Cardinal Health (CAH) delivered a robust fiscal 2026 performance, exceeding guidance by over $2.00 per share on a normalized basis, with every operating segment posting double-digit earnings growth. The company’s CEO, Jason Hollar, emphasized the breadth of its success during the 2026 Global Healthcare Conference, noting that the depth and diversification of its opportunities reflect a strong management team and a mature, evolving industry.
Financial highlights included a 25% increase in specialty pharmaceutical distribution, driven by strategic acquisitions, customer onboarding, and operational excellence—including four bolt-on deals in the latest quarter. Meanwhile, generics revenue growth remained steady at around 2% to 3% long-term, supported by market penetration that has sustained near 90% for seven years.
The company is on track to meet its $10 billion cumulative free cash flow target, having already reached approximately 90% of that goal. Guidance for the pharma business was raised to align with its updated long-range plan, while biopharma solutions and at-home logistics solutions—expanding with three new automated distribution centers—continue to expand.
In operational shifts, Cardinal Health reduced its global medical products distribution footprint by over half, despite tariff challenges, while integrating Solaris Health’s nuclear pharmaceutical business into its urology-focused managed services platform. Strategic acquisitions, including AdaptHealth’s diabetes segment (expected to close in H2 2027) and Strive’s urology durable medical equipment, further solidified its market position.
Hollar underscored the turnaround in Global Medical Products Distribution, citing substantial losses from prior years and growth despite tariff headwinds. The company also distinguished its at-home logistics model from in-home patient care, emphasizing its expertise in healthcare logistics rather than direct patient care.
The stock, trading at approximately $234.89, reflects a price-to-earnings ratio of 32.4 times normalized earnings. Eligible patient coverage for continuous glucose monitors stands at 35%, highlighting ongoing advancements in at-home healthcare solutions.
